Sesotho
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Lihlahisoa tsa lihlopha
Lihlahisoa tse hlahisitsoeng
Matlapa a Lenopril a Matlafatsang Taolo ea Khatello ea Mali le Bophelo bo Botle ba Pelo

Matlapa a Lenopril a Matlafatsang Taolo ea Khatello ea Mali le Bophelo bo Botle ba Pelo
Telmisartan Betere antihypertensive Ho sireletsa renal

Telmisartan Betere antihypertensive Ho sireletsa renal
Flumazenil Mohanyetsi oa Moamoheli oa GABAA ea Khethiloeng le Likopo tsa eona tsa Phekolo

Flumazenil Mohanyetsi oa Moamoheli oa GABAA ea Khethiloeng le Likopo tsa eona tsa Phekolo
Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated

Dabrafenib Phekolo e Lebisitsoeng bakeng sa Kankere ea BRAF-Mutated
Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic

Tirzepatide Dual GLP-1 le GIP Receptor Agonist bakeng sa Taolo ea Boima le Taolo ea Glycemic
Cisapride Gastric Stimulant bakeng sa Indigestion le Mathata a Ts'ila

Cisapride Gastric Stimulant bakeng sa Indigestion le Mathata a Ts'ila
YK-11 SARM e Matla bakeng sa Kaho ea mesifa, Matla a Matla, le Myostatin Inhibition

YK-11 SARM e Matla bakeng sa Kaho ea mesifa, Matla a Matla, le Myostatin Inhibition
Ostarine (MK-2866) SARM e fapaneng bakeng sa Khōlo ea Mesifa, Tahlehelo ea Mafura le 'Mele oa Recomposition

Ostarine (MK-2866) SARM e fapaneng bakeng sa Khōlo ea Mesifa, Tahlehelo ea Mafura le 'Mele oa Recomposition
MK-677 Motsoako o Ikhethileng oa Khōlo ea Mesifa, Mamello, le Pholiso

MK-677 Motsoako o Ikhethileng oa Khōlo ea Mesifa, Mamello, le Pholiso
0102030405
Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers
Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Trametinib Kinase Inhibitor Targeting BRAF V600 Mutation-Positive Cancers

Theko ea litšupiso: USD 8-15/g

  • Lebitso la Sehlahiswa Trametinib
  • Nomoro ea CAS. 871700-17-3
  • MF C26H23FIN5O4
  • MW 615.402623
  • Botenya 1.743
  • Sebaka se qhibilihang 293-303°C
Iteanye le rona
lintlha tsa sehlahisoa

Tlhaloso e Felletseng

Trametinib ke "kinase inhibitor" e matla le e khethang e sebelisoang haholo kalafong ea melanoma e sa tsitsang kapa ea metastatic ka phetoho ea BRAF V600, hammoho le mefuta e ikhethileng ea mofets'e o tsoetseng pele kapa oa metastatic o seng o nyane oa lisele tsa matšoafo. Sengoliloeng sena se hlahloba mokhoa oa ts'ebetso, matšoao a kliniki, le melemo ea trametinib kalafong ea mofets'e oa BRAF V600.

I. Ho utloisisa Trametinib:
A. Oral, e matla, le e khethang kinase inhibitor
B. Ke oa sehlopha sa MEK inhibitors
C. E thibela mosebetsi oa kinase oa MEK1 le MEK2
D. E thibela letšoao la ERK1 le ERK2 le tlase

II. Matšoao a Kliniki:
A. Melanoma e sa senyeheng kapa e metastatic e nang le phetoho ea BRAF V600:
Phekolo e kopaneng le dabrafenib mesylate
B. Kalafo ea adjuvant ea morao-rao bakeng sa BRAF V600 mutation-positive melanoma:
Kalafo ea Adjuvant ka dabrafenib mesylate ka mor'a ho tsoa ka ho feletseng

17161152266097be

III. Seabo ho Kankere e Seng e Nyenyane ea Letšoafo ea Sele:

A. Kankere ea matšoafo ea sele e seng nyane joalo ka sesosa se ka sehloohong sa mafu le lefu

B. Sekhahla sa phetoho ea liphatsa tsa lefutso tsa BRAF le ho ata ha phetoho ea BRAF V600E

Thibelo ea C. Trametinib ho lisele tsa BRAF V600 mutation-positive melanoma


IV. Mokhoa oa ts'ebetso:

A. Thibelo e ka fetoloang ea mitogen-activated extracellular signal-regulated kinase (MEK) 1 le MEK2

B. Tšusumetso tseleng ea MAPK le protheine ea MEK

C. Thibelo ea ho ata ha lisele le tsela e tlase ea ERK


V. Postoperative Adjuvant Therapy:

A. Melemo ea phekolo e lebisitsoeng ea motsoako le Dabrafenib le Trametinib

B. Melemo ea nako e telele, e tšoarellang ea recurrence-free (RFS) ho bakuli ba kotsing e kholo ea III BRAF mutation-positive melanoma.



Trametinib, "kinase inhibitor" e lebisitsoeng ho eona, e bonts'a katleho e kholo kalafong ea mofets'e oa BRAF V600, haholo-holo o ke keng oa qojoa kapa oa metastatic melanoma le mefuta e itseng ea mofetše oa matšoafo oa sele e seng nyane. Mokhoa oa eona oa ts'ebetso, o thibelang mosebetsi oa MEK1 le MEK2 kinase, o lebisa ho theosa le ERK ho thibela tsela le ho thibela ho ata ha lisele. Trametinib, hammoho le dabrafenib mesylate, e fana ka melemo ea kalafo maemong a tsoetseng pele le a adjuvant bakeng sa bakuli ba BRAF V600 mutation-positive melanoma.
Ikopanye le rona bakeng sa likeletso tsa meriana le tlhaiso-leseling ea litheko ho ntlafatsa tlhokomelo ea bakuli.

Tlhaloso

171611254334271z